Abstract:Guided by molecular docking, a commonly used open-chain linker was cyclized into a five-membered pyrrolidine to lock the overall conformation of the propeller-shaped molecule. Different substituents were introduced into the pyrrolidine moiety to block oxidative metabolism. Surprisingly, it was found that a small methyl substituent could be used to alleviate the oxidative metabolism of pyrrolidine while maintaining or enhancing potency, which could be described as a "magic methyl". Further optimization around the "3rd blade" of the propeller led to identification of a series of potent and selective PI3Kδ inhibitors. Among them, compound 50 afforded an optimum balance of PK profiles and potency. Oral administration of 50 attenuated the arthritis severity in a dose-dependent manner in a collagen-induced arthritis model without obvious toxicity. Furthermore, 50 demonstrated excellent pharmacokinetic properties with high bioavailability, suggesting that 50 might be an acceptable candidate for treatment of inflammatory diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00004?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00004</a>.Binding affinities of 50 with 164 kinases (Table S1); predicted results of compound 43 from the CYP3A4, CYP2D6, and CYP2C9 models, respectively, in SMARTCyp (Tables S2–S4); effects of compound 50 and idelalisib on normal cell viability (Table S5); binding free energy (ΔGbindcal) for idelalisib/PI3Kδ complexes (Table S6); binding free energy (ΔGbindcal) for compound 50/PI3Kδ complexes (Table S7); cocrystal structure of 1 in PI3Kδ (Figure S1); docking model of compound 29 in PI3Kδ (Figure S2); pre-experiments of selected compounds and dexamethasone in collagen-induced arthritis models (Figure S3); snapshots of the idelalisib/PI3Kδ complex along the dynamic simulation time for 100th, 200th, 300th, 400th, and 500th ns (Figure S4); snapshots of the compound 50/PI3Kδ complex along the dynamic simulation time at 100th, 200th, 300th, 400th, and 500th ns (Figure S5); therapeutic efficacy of 50 in mice-established collagen-induced arthritis (Figure S6); HPLC spectra of compound 50 (Figure S6); 1H NMR spectra of compounds 26, 30, 45, 46, 47, 49, and 50 (Figures S8, S9, S10, S11, S12, S13, and S14, respectively); and biological assay methods: (1) kinase profile assay and IC50 test; (2) class I PI3K isoform-selective cellular assays (SKOV-3, 786-O, RAW 264.7, and RAJI cell lines); (3) basophil activation assay in HWB; (4) B cell activation assay in HWB; (5) primary human T-cell proliferation assays; (6) microsome stability assay; (7) pharmacokinetic study; (8) collagen-induced arthritis (CIA) model and treatment; and (9) histological examination (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_003.csv">CSV</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a> was used for docking in PI3Kδ of compounds 10, 29, 43, and 50 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_002.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Advances in the Discovery of Novel Inhaled PI3K Inhibitors for the Treatment of Asthma

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD

Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of (S)-2-(1-(4-amino-3-(3-fluoro-4-methoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3h)-one (Ihmt-Pi3kδ-372) As a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Design, Synthesis, and Development of pyrazolo[1,5- a]pyrimidine Derivatives as a Novel Series of Selective PI3K δ Inhibitors: Part I-Indole Derivatives

Discovery of ( S )-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1 H -pyrazolo[3,4- d ]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3 H )-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.

Discovery of (S)-2-amino-n-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) As a Potent and Selective Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitor.

Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β 2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket

Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.

Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases

Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer

The Discovery of MORF-627, a Highly Selective Conformationally-Biased Zwitterionic Integrin αvβ6 Inhibitor for Fibrosis

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor